Moleculin Biotech (MBRX)
NASDAQ:MBRX
Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$2.42
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.42
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$1.79 - $24.00
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$15.37M
Enterprise Value$4.95M
Total Cash (Recent Filing)$10.32M
Total Debt (Recent Filing)$326.00K
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 19, 2026EPS Estimate
-1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.98
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.80
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$16.00Price Target Upside561.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety And Efficacy Data For AnnamycinRobust pooled safety and efficacy signal (no cardiotoxicity across 90 patients and strong remission rates) materially strengthens Annamycin’s long-term clinical value proposition versus traditional anthracyclines. Durable non-cardiotoxic profile can expand patient eligibility and enable broader combo strategies and market adoption if confirmed in pivotal readouts.
Strengthening Global Intellectual PropertyExpanded patent coverage, including Hong Kong through 2040, supports sustained market exclusivity in key geographies and underpins commercialization planning. Durable IP protection reduces competitive entry risk, enhances licensing or partnering leverage, and preserves potential future revenue streams if clinical success leads to approval.
Low Leverage On The Balance SheetVery low debt lessens near-term solvency pressure and gives management flexibility when navigating development milestones. Structurally, low leverage reduces bankruptcy risk and preserves optionality for strategic financing or partnerships that can support mid-term development and commercialization activities.
Bears Say
Zero Revenue And Sustained LossesThe company remains pre-commercial with no product revenue and substantial recurring net losses. Over the medium term this means value creation hinges entirely on trial success and future commercialization; persistent losses erode equity and raise the bar for capital raises or partner deals to fund growth.
High And Persistent Cash BurnSustained negative operating and free cash flow implies ongoing reliance on external capital. This structural cash-burn profile increases dilution or debt risk over the next 2–6 months if trial milestones or financing events are delayed, constraining strategic flexibility and raising financing cost or partnership dependence.
Binary Clinical-stage Development RiskThe business model is highly dependent on a single pivotal program outcome. Trial results are binary and will materially determine commercial viability; failure or ambiguous readouts would significantly impair the company’s ability to monetize IP and necessitate urgent financing or strategic alternatives.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.79 and its highest was $24.00 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $15.37M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 59 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.333 by -$1.207.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.54.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.333. Following the earnings report the stock price went down -4.091%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(561.16% Upside)
Technical Analysis
Ownership Overview
20.61% Insiders
0.56% Mutual Funds
1.41% Other Institutional Investors
76.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---